Amedisys
Stock Forecast, Prediction & Price Target
Amedisys Financial Estimates
Amedisys Revenue Estimates
Amedisys EBITDA Estimates
Amedisys Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $2.21B N/A | $2.22B 0.41% | $2.23B 0.59% | Avg: $2.49B Low: $2.42B High: $2.58B avg. 11.65% | Avg: $2.62B Low: $2.58B High: $2.67B avg. 5.18% | ||
Net Income
% change YoY
| $209.07M N/A | $118.60M -43.26% | $-9.74M -108.21% | Avg: $155.90M Low: $132.67M High: $164.29M avg. 1699.52% | Avg: $159.3M Low: $144.97M High: $151.22M avg. 2.17% | ||
EBITDA
% change YoY
| $329.92M N/A | $256.44M -22.27% | $216.91M -15.41% | Avg: $312.80M Low: $303.90M High: $324.24M avg. 44.20% | Avg: $329.02M Low: $324.39M High: $335.10M avg. 5.18% | ||
EPS
% change YoY
| $6.41 N/A | $3.65 -43.05% | -$0.3 -108.21% | Avg: $4.67 Low: $4.07 High: $5.04 avg. 1656.66% | Avg: $4.53 Low: $4.45 High: $4.64 avg. -2.99% | ||
Operating Expenses
% change YoY
| $728.84M N/A | $778.99M 6.88% | $834.47M 7.12% | Avg: $651.99M Low: $633.44M High: $675.85M avg. -21.86% | Avg: $685.80M Low: $676.16M High: $698.47M avg. 5.18% | ||
FAQ
What is Amedisys stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 850.84% in 2025-2026.
We have gathered data from 6 analysts. Their low estimate is 132.67M, average is 155.90M and high is 164.29M.
What is Amedisys stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 8.41% in 2025-2026.
We have gathered data from 7 analysts. Their low revenue estimate is $2.42B, average is $2.49B and high is $2.58B.
What is Amedisys stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 826.83% in 2025-2026.
We have gathered data from 6 analysts. Their low earnings per share estimate is $4.07, average is $4.67 and high is $5.04.
What is the best performing analyst?
In the last twelve months analysts have been covering Amedisys stock. The most successful analyst is Frank Morgan.